Siemens Healthineers and Mayo Clinic Expand Strategic Collaboration to Enhance Patient Care Through Advanced Technology

Siemens Healthineers and Mayo Clinic are expanding their strategic collaboration to enhance patient care for neurodegenerative disease and the management of prostate cancer and metastatic liver tumors. The two organizations have signed an agreement that will improve care for those disease states and expand access to new imaging and interventional technologies. 

Initial areas for collaboration include: 

Neurodegenerative disease: Advancement and clinical translation of AI-enabled MRI protocols for improved diagnostic accuracy and patient monitoring 

Surgical care pathway innovation: Applying digital twin technologies to re-imagine how patients experience surgery, enhancing their experience and improving operational efficiency 

Prostate cancer: Jointly investigating the role of AI in minimizing biopsies and integration of minimally invasive, advanced imaging into diagnostic and therapeutic procedures 

Minimally invasive, image-guided interventional suites: Clinical translation of image-guided technologies for the precise detection and treatment of liver metastases 

Ultra-high-field MRI innovation center: Clinical adoption and translation of ultra-high-field MRI protocols, taking advantage of the technology’s high resolution and enhanced contrast for diagnostic and surgical planning in complex neurological disease states 

Whole Body PET/CT & PET/MR innovation center: Adoption and clinical integration of whole-body PET/CT emphasizing theranostics treatment for certain cancers and simultaneous anatomical and metabolic MR imaging to enable precise diagnostic and therapeutic planning 

“Our goal is to make care more precise, less invasive, and more responsive to each patient’s needs,” said Eric Williamson, M.D., professor and chair, diagnostic radiology, Mayo Clinic. “By expanding our collaboration, we can bring advanced imaging, artificial intelligence, and innovative treatment approaches directly into everyday clinical care, potentially helping patients receive earlier diagnoses, more personalized treatment plans, and better outcomes.” 

Added John Kowal, president and head of the Americas at Siemens Healthineers: “Improving the diagnosis and treatment of neurodegenerative disease and cancer is core to our purpose as a company. Our collaboration with Mayo Clinic creates significant opportunities to help extend the quantity and quality of patients’ lives.”